Lexaria shareholders re-elect all directors; McKechnie gets 54% support, Baxter 62%

Lexaria Bioscience Corp.

Annual meeting on Jan 14, 2025: 9,761,279 shares (55.93% of outstanding) represented.
Directors elected: Bunka 89%, Docherty 98%, Baxter 62%, McKechnie 54%, Reese 90%, Christopher 98%, Bhullar 98%.
Say-on-pay frequency approved every three years with 66% of votes cast; advisory compensation passed at 97%.
Warrant exercise proposal approved by 70% of votes cast; auditor Malone Bailey LLP ratified with 98%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.